TTK Healthcare Limited has recommended a final dividend of ₹10 per equity share for FY2025-26, its board resolved on May 30, 2026. The announcement coincides with the company's submission of financial results for the quarter ended June 30, 2026, filed with the NSE on August 6, 2026. The dividend marks the fifth consecutive year in which the Chennai-based healthcare company has maintained an identical per-share payout of ₹10.

Dividend Details and Yield

The declared final dividend of ₹10 per equity share carries a face value context relevant to shareholders on record as of the eligible date. With market price data unavailable in the current filing window, a precise dividend yield calculation cannot be confirmed at this time. Investors should compute yield as ₹10 divided by the prevailing market price at the time of investment to arrive at an accurate return figure. The dividend is subject to shareholder approval at the upcoming Annual General Meeting before disbursement.

Dividend History and Trend Analysis

TTK Healthcare's dividend track record over the past eight years reveals a clear progression followed by a plateau:

The data shows the company doubled its dividend payout from ₹5 to ₹10 in FY2021-22 and has held that level without variation through five annual cycles. There has been no incremental increase since the step-up, indicating a stable but non-growing absolute payout policy. The FY2019-20 dip to ₹3 per share coincided with widespread corporate cash conservation during the COVID-19 disruption period.

Company Background

TTK Healthcare Limited, part of the diversified TTK Group, operates across pharmaceuticals, medical devices, and consumer healthcare products. Its product portfolio includes brands in personal care, family planning, and animal health segments. The company is listed on NSE under the symbol TTKHLTCARE with ISIN INE910C01018. Being part of the TTK Group, which also includes TTK Prestige, the company benefits from established brand equity and distribution infrastructure across India.

What This Means for Investors

The unchanged ₹10 dividend for FY26 signals consistency in capital return policy but offers no growth in absolute income for existing shareholders compared to the prior four years. For income-focused investors, the flat trajectory since FY2021-22 suggests the board is prioritising retained earnings or capital allocation elsewhere rather than raising the per-share payout. The Q1 FY27 results filed alongside this dividend cycle will be the next data point for assessing whether earnings momentum supports a potential dividend increase in the coming year. Investors tracking total shareholder return should evaluate the ₹10 payout relative to the stock's current trading price to benchmark it against fixed-income alternatives and sector peers in the mid-cap healthcare space.

The board meeting for Q1 FY27 results was held on August 6, 2026, and all regulatory disclosures have been made to NSE in compliance with SEBI listing obligations.